Page 30 - MemoriaBBN-Eng

SCIENTIFIC PROGRAMMES

Dendrimer Group for Biomedical Applications,
Rafael Gómez Ramírez
Universidad de Alcalá

(GDAB-UAH)

José Luis Pedraz Muñoz
Micro and Nano technologies, Biomaterials and
Cells Research Group (NANOBIOCEL)

Oncogenesis and Antitumor Group of the Research

Ramón Mangues Bafalluy
Institute, Hospital de la Santa Cruz y San Pablo
(GOA-HSCSP)

Molecular immunobiology laboratory,

Ma Ángeles Muñoz Fernández
Hospital General Universitario Gregorio Marañón
(LIBM-HGUGM)

Colloidal and Interfacial Chemistry Group of the

Concepción Solans Marsà
Advanced Chemistry Institute of Cataluña, CSIC
(QCI-CSIC)

óAppliedMolecularChemistryGroup, Centrode

Ramn Martínez Máñez
Reconocimiento Molecular y Desarrollo Tecnológico
de la Universidad Politécnica de Valencia (IQMA-

IDM-UPV)

a) Molecular diagnosis and biosensors:
Strategic lines

of research This line covers new diagnosis approaches and strategies based on the latest advan-
cements in micro(nano)technology and biotechnology. The knowledge obtained in
of the
these areas and the possibility of combining both sciences foretell the emergence of
programme
a new generation of tools for more precise, flexible and effective diagnoses. It also
has enormous potential for detecting a wider range of more robust and sensitive

biomarkers. The physical properties of materials, nanostructured surfaces and na-
noparticles are the basis for constructing biofunctional hybrid materials as the result

of the combination of organic (biomolecules) and inorganic elements, which can be

described as a clear advancement in biosensors based on novel nanobiotechnological
approaches.

This line gives priority to projects aimed at solving clinical problems where the appli-

cation of systems based on biosensors and specific biomarker detectors provides a
feasible solution and a clear advantage in diagnosis. Priority will preferably be given

to the development of technologies in the context of relevant clinical needs.

This includes both the use of biomarkers for tracking the progression of a certain

disease, and the recognition of targets for specific therapies. Techniques based on
spectroscopic NMR, specific antibodies, etc., will be a preferred object in this line,

as will be the use of highly specific and even multiplexed nanobiosensors. The use 13
20
of these techniques will allow diagnoses with a stronger biological basis and more T
reliable results, which translates into greater precision in diagnosing different patho- R
PO
logies.
E
L R
The general objective of this strategic line is to provide new diagnosis tools to im- A
prove and protect public health based on novel micro(nano)biotechnological ap- NU
N
proaches. In the long-term, research in this line seeks to overcome challenges that A
/
current diagnosis methods have not been able to overcome and to provide alterna- BN
tive in those areas where current technology limitations compromise the health of B
R-
individuals and the quality of life of the society as a whole.
BE
CI

30